Dare Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 25, 2020, details the results of the annual meeting of stockholders for Dare Bioscience, Inc. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol "DARE".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Four proposals were voted upon at the annual meeting:
- Proposal 1 (Election of Directors): Stockholders elected Cheryl R. Blanchard and Sabrina Martucci Johnson as Class III directors for a three-year term.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Mayer Hoffman McCann P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Proposal 3 (Say-on-Pay): Stockholders approved, on an advisory basis, the 2019 compensation of named executive officers.
- Proposal 4 (Frequency of Say-on-Pay): Stockholders voted to hold the advisory vote on executive compensation every year.
Guidance, Outlook, and Management Commentary
Based on the results of Proposal 4, management decided to include the stockholder advisory vote on executive compensation in proxy materials every year until the next required vote on frequency. The filing contains no financial guidance, risk factors, or discussion of contingencies.
Investor Verification Checklist
- Verify the specific vote counts for director elections and auditor ratification in the definitive proxy statement filed on April 22, 2020.
- Confirm the implementation of the annual "say-on-pay" frequency in future proxy materials.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K does not contain financial metrics.